#67 Notable Clinical Interest
Emerging findings or policy developments worth monitoring closely.
Clinicians need evidence-based guidance on CBD safety in adolescents since patients and families increasingly seek it for conditions like anxiety and epilepsy, yet limited data exists on long-term neurodevelopmental effects during critical brain maturation periods. Understanding the distinction between THC and CBD’s safety profiles helps clinicians counsel teens appropriately and identify which products warrant caution versus those with established efficacy. Legal and regulatory gaps mean clinicians must educate patients about product quality, contamination risks, and drug interactions that could affect treatment outcomes in this vulnerable population.
Adolescent cannabis use carries documented risks to neurodevelopment, though research has historically focused on THC rather than CBD. While CBD is often marketed as a safer alternative with fewer psychoactive effects, the limited evidence in teen populations means that potential risks to the developing brain remain incompletely characterized. Current legal status varies by jurisdiction, creating confusion about accessibility and age restrictions that may differ from actual safety data. Clinicians should counsel adolescent patients and their families that despite CBD’s legal availability in many areas, the safety profile in this age group has not been rigorously established, and the developing brain may be uniquely vulnerable to cannabinoid effects. When evaluating teen patients who report or may be using CBD products, practitioners should discuss neurodevelopmental concerns and consider that legal availability does not equate to proven safety in minors.
“The neurodevelopmental concerns we have are primarily grounded in THC literature, and while CBD appears pharmacologically distinct, we simply don’t have the long-term human studies in adolescents to claim it’s developmentally safe, so I counsel families to be cautious pending better evidence.”
🧠 While cannabidiol (CBD) is often marketed as a non-intoxicating, safer alternative to THC, the existing evidence base for its safety in adolescents remains limited and incomplete. The developing teenage brain is particularly vulnerable to cannabinoid exposure during critical periods of neural maturation, yet most mechanistic research has focused on THC rather than CBD, leaving important gaps in our understanding of how CBD alone—or in combination with trace THC in commercial products—might affect adolescent neurodevelopment. Clinicians should be aware that CBD products are largely unregulated, frequently contain unlisted THC or other contaminants, and may interact with medications commonly prescribed to teenagers. When counseling adolescents and their parents about cannabis use, a precautionary approach is warranted: emphasizing that “natural” or “CBD-only” products do not necessarily equate to safety during a period of active brain development, discussing the
This topic comes up in consultations often.
Dr. Caplan offers clinical context on evolving cannabis policy and its real-world implications for patients.
Book a consultation →💬 Join the Conversation
Have a question about how this applies to your situation? Ask Dr. Caplan →
Want to discuss this topic with other patients and caregivers? Join the forum discussion →
Have thoughts on this? Share it:
